Results 91 to 100 of about 823,777 (226)

Palmitoyl Acyltransferase Zdhhc17 Promotes Functional Recovery After Spinal Cord Injury by Targeting the Nuclear Transport Factors Kpna2 and Ipo9

Advanced Science, EarlyView.
In this study, we demonstrate that Zdhhc17, acting as a PAT, suppresses neuronal apoptosis and promotes axon regeneration after injury, thereby enhancing functional recovery following SCI. In this context, Kpna2 and Ipo9 serve as novel palmitoylation substrates of Zdhhc17, whose palmitoylation prevents the injury‐induced degradation of their proteins ...
Meixuan Chen, Huan Chen, Sining Ding, Fan Liu, Xiaofei Zheng, Yuan Wang, Ruitu Tian, Huan Li, Peilin Liu, Le Hu, Bin Liu, Limin Rong, Mangmang Li   +12 more
wiley   +1 more source

Cyclosporin A-Based PROTACs Can Deplete Abundant Cellular Cyclophilin A without Suppressing T Cell Activation

Molecules
Cyclophilin A (CypA), the cellular receptor of the immunosuppressant cyclosporin A (CsA), is an abundant cytosolic protein and is involved in a variety of diseases.
Katharina Hilbig, Russell Towers, Marc Schmitz, Martin Bornhäuser, Petra Lennig, Yixin Zhang   +5 more
doaj   +1 more source

Degrading GPX4 via Biomimetic Nanoparticle‐Mediated In Situ Synthesis of Deep‐Learning‐Designed Binder‐Degron Chimeras for Prostate Cancer Therapy

Advanced Science, EarlyView.
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang, Ye An, Na Zeng, Mei‐Cheng Liu, Jian‐Xuan Sun, Xi Gong, Jin‐Zhou Xu, Shao‐Gang Wang, Qi‐Dong Xia   +8 more
wiley   +1 more source

Insights into the Design of MYC-Targeting Proteolysis Targeting Chimeras (PROTACs)

Molecules
The oncogenic transcription factor MYC is a key driver of the development and progression of various types of cancer, but its intrinsically disordered structure and dependence on protein–protein interactions make it a difficult therapeutic target.
Abdallah M. Alfayomy, Sven Hagemann, Matthias Schmidt, Ali Fouad, Mohamed Ayman El-Zahabi, Stefan Hüttelmaier, Wolfgang Sippl   +6 more
openaire   +3 more sources

PROTACs in Antivirals: Current Advancements and Future Perspectives

Molecules
Proteolysis-targeting chimera (PROTAC) technology has demonstrated remarkable progress in tumor therapy, attributed to its unique capability of catalytically degrading “undruggable” targets. In the context of the ongoing global health threat posed by the
Jiacheng Jin, Mengxiang Quan, Xueyan Cao, Yun Zhang, Xiangwei Xu, Zunyuan Wang   +5 more
doaj   +1 more source

PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives

MedComm
AbstractLeukemia is a heterogeneous group of life‐threatening malignant disorders of the hematopoietic system. Immunotherapy, radiotherapy, stem cell transplantation, targeted therapy, and chemotherapy are among the approved leukemia treatments. Unfortunately, therapeutic resistance, side effects, relapses, and long‐term sequelae occur in a significant
André T. S. Vicente, Jorge A. R. Salvador   +1 more
openaire   +3 more sources

Transfer RNA‐Derived Small RNA‐5’tiRNAGln Drives HNRNPC Phase Separation to Promote Breast Cancer Bone Metastasis by Regulating IGF1R

Advanced Science, EarlyView.
This study reveals that 5'tiRNA‐Gln interacts with hnRNPC to promote IGF1R liquid‐liquid phase separation, which drives ERK1/2 signaling activation, EMT, and breast cancer bone metastasis. These findings highlight a novel mechanism of breast cancer bone metastasis and potential therapeutic target in metastatic breast cancer.
Bingnan Wang, Dongsong Liu, Xiaozhi Fan, Jiale Fan, Xuesi liu, Yu Wang, Zixin Wang, Mo Cheng, Ping Zhou, Wangjun Yan   +9 more
wiley   +1 more source

Design and synthesis of modular proteolysis targeting chimeras (PROTACs) for the degradation of Clostridium botulinum type A neurotoxin (BoNT/A)

, 2022
reservedBotulinum neurotoxins (BoNTs) are the most potent toxins known and can be easily produced and isolated in large amount, so that they are considered potential bioterrorism agents.
CECCHIN, ALESSIA
core  

Recent advances in targeting protein degradation for tumor immunotherapy

Journal of Hematology & Oncology
Immunotherapy has revolutionized the landscape of cancer treatment, yet its efficacy is often limited by drug resistance, the immunosuppressive tumor microenvironment (TME), and the “undruggable” nature of key immunoregulatory proteins.
Shuai Li, Yushan Jin, Huanhuan Wu, Hong Yuan, Jingyuan Zhao   +4 more
doaj   +1 more source

PROTACs improve selectivity for targeted proteins

Acta Materia Medica
Proteolysis targeting chimera (PROTAC) technology has emerged as a powerful tool in drug discovery that enables targeted protein degradation through a unique bifunctional approach.
Lihua Liu, Xian Guan, Jiezhen Zhuo, Xifeng Wu, Xin Han   +4 more
doaj   +1 more source